Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CUE Cue Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: CUE
Price (delayed)
$0.638
Market cap
$48.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.64
Enterprise value
$39.95M
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the
Highlights
CUE's debt is down by 45% year-on-year and by 20% since the previous quarter
The EPS is up by 40% YoY and by 11% QoQ
The gross profit is down by 14% since the previous quarter but it is up by 14% year-on-year
CUE's revenue is down by 14% since the previous quarter but it is up by 14% year-on-year
The company's equity has shrunk by 78% YoY and by 62% QoQ
Cue Biopharma's quick ratio has shrunk by 61% YoY and by 47% QoQ
Key stats
What are the main financial stats of CUE
Market
Valuations
Earnings
Shares outstanding
75.35M
Market cap
$48.07M
Enterprise value
$39.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.99
Price to sales (P/S)
5.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5
Revenue
$7.99M
Gross profit
$7.99M
Operating income
-$41.13M
Net income
-$40.58M
EBIT
-$39.9M
EBITDA
-$37.52M
Free cash flow
-$34.78M
Per share
Balance sheet
Liquidity
EPS
-$0.64
EPS diluted
-$0.64
Free cash flow per share
-$0.47
Book value per share
$0.11
Revenue per share
$0.11
TBVPS
$0.3
Total assets
$22.25M
Total liabilities
$15.67M
Debt
$7.13M
Equity
$6.58M
Working capital
$433,000
Debt to equity
1.08
Current ratio
1.03
Quick ratio
0.98
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-469.5%
Gross margin
100%
Net margin
-507.9%
Operating margin
-514.7%
Return on assets
-114.7%
Return on equity
-228.4%
Return on invested capital
-1,999.7%
Return on capital employed
-590.6%
Return on sales
-499.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CUE stock price
How has the Cue Biopharma stock price performed over time
Intraday
-0.93%
1 week
-3.54%
1 month
-15.51%
1 year
-59.87%
YTD
-41.47%
QTD
-29.97%
Financial performance
How have Cue Biopharma's revenue and profit performed over time
Revenue
$7.99M
Gross profit
$7.99M
Operating income
-$41.13M
Net income
-$40.58M
Gross margin
100%
Net margin
-507.9%
Cue Biopharma's operating margin has increased by 30% YoY but it has decreased by 15% from the previous quarter
CUE's net margin is up by 29% year-on-year but it is down by 16% since the previous quarter
The company's operating income rose by 20% YoY
The net income has grown by 19% YoY
Price vs fundamentals
How does CUE's price correlate with its fundamentals
Growth
What is Cue Biopharma's growth rate over time
Valuation
What is Cue Biopharma stock price valuation
P/E
N/A
P/B
5.99
P/S
5.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5
The EPS is up by 40% YoY and by 11% QoQ
The company's equity has shrunk by 78% YoY and by 62% QoQ
The P/B is 50% above the 5-year quarterly average of 4.0 and 43% above the last 4 quarters average of 4.2
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 65.8 and 11% lower than the last 4 quarters average of 6.7
CUE's revenue is down by 14% since the previous quarter but it is up by 14% year-on-year
Efficiency
How efficient is Cue Biopharma business performance
The ROIC has shrunk by 80% QoQ
Cue Biopharma's return on equity has shrunk by 78% YoY and by 33% QoQ
The ROA has contracted by 48% YoY and by 22% from the previous quarter
The ROS is up by 28% YoY but it is down by 16% QoQ
Dividends
What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CUE.
Financial health
How did Cue Biopharma financials performed over time
The total assets is 42% greater than the total liabilities
Cue Biopharma's quick ratio has shrunk by 61% YoY and by 47% QoQ
The total assets has dropped by 59% year-on-year and by 31% since the previous quarter
CUE's debt is 8% greater than its equity
CUE's debt to equity has soared by 151% YoY and by 112% QoQ
The company's equity has shrunk by 78% YoY and by 62% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.